XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Non-controlling Interest (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 05, 2018
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Noncontrolling Interest          
Related Party Transaction, Expenses from Transactions with Related Party $ 441,000        
Research and Development Expense   $ 914,000 $ 4,144,000 $ 4,152,000 $ 9,156,000
SYN Biomics          
Noncontrolling Interest          
Equity interest by parent   83.00%   83.00%  
Accumulated net loss attributable to the non-controlling interest   $ 2,800,000 2,800,000 $ 2,800,000 2,800,000
Cedarssinai Medical Center [Member]          
Noncontrolling Interest          
Number Of Common Stock To Be Issued 50,000 0   0  
Research and Development Expense   $ 134,000 $ 108,000 $ 225,000 $ 318,000
Fair Value Of Shares Issued $ 285,000        
Cedarssinai Medical Center [Member] | SYN Biomics          
Noncontrolling Interest          
Additional Number Of Common Stock To Be Issued 2,420,000        
Number Of Common Stock To Be Held By Related Party 7,480,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 17.00%